HIF1A and non-small cell lung carcinoma: This is driven by the upregulation of HIF-1α, promoting survival under hypoxic conditions leading to NSCLC aggressiveness and resistance to target therapy and chemotherapy (Liu C. et al., 2021; Ziółkowska-Suchanek, 2021; Lu et al., 2020).